Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Zhang, Yin ^a   Hong, Hao ^b   Engle, Jonathan W ^a   Bean, Jero ^b   Yang, Yunan ^b   Leigh, Bryan R ^c   Barnhart, Todd E ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TRACON Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRACETIC ACID; CHELATING AGENT; COPPER 64; ENDOGLIN; MONOCLONAL ANTIBODY; TRC 105; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; CELL SURFACE RECEPTOR; COPPER; DIAGNOSTIC AGENT; ENDOGLIN PROTEIN, MOUSE; ENG PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; LEUKOCYTE ANTIGEN; SIGNAL PEPTIDE; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MOLECULAR STABILITY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; STAINING; TISSUE DISTRIBUTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, CELL SURFACE; STAINING AND LABELING; TISSUE DISTRIBUTION;

EID: 83055173264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028005     Document Type: Article

References (38)

1. McCardle RJ, Harper PV, Spar IL, Bale WF, Andros G, et al. (1966) Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J Nucl Med 7: 837-847.
2. Wu AM, (2009) Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50: 2-5.
3. Wu AM, Senter PD, (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146.
4. Wadas TJ, Wong EH, Weisman GR, Anderson CJ, (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 110: 2858-2902.
5. Blower PJ, Lewis JS, Zweit J, (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23: 957-980.
6. Cai W, Wu Y, Chen K, Cao Q, Tice DA, et al. (2006) In vitro and in vivo characterization of 64Cu-labeled Abegrin™, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 66: 9673-9681.
7. Niu G, Li Z, Xie J, Le QT, Chen X, (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50: 1116-1123.
8. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, et al. (2007) [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 104: 12462-12467.
9. Liu Z, Li ZB, Cao Q, Liu S, Wang F, et al. (2009) Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med 50: 1168-1177.
10. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, et al. (2011) cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32: 4151-4160.
11. Dearling JLJ, Voss SD, Dunning P, Snay E, Fahey F, et al. (2011) Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody. Nucl Med Biol 38: 29-38.
12. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, et al. (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42: 213-221.
13. Seo JW, Zhang H, Kukis DL, Meares CF, Ferrara KW, (2008) A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem 19: 2577-2584.
14. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, et al. (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48: 1327-1337.
15. Wadas TJ, Anderson CJ, (2006) Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 1: 3062-3068.
16. Huang CW, Li Z, Cai H, Shahinian T, Conti PS, (2011) Biological stability evaluation of the alpha2beta1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem 22: 256-263.
17. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, et al. (2009) 64Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol 36: 277-285.
18. Wadas TJ, Wong EH, Weisman GR, Anderson CJ, (2007) Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 13: 3-16.
19. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M, (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 86: 12-19.
20. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, et al. (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8: 135-143.
21. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, et al. (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14: 1931-1937.
22. Zhang Y, Yang Y, Hong H, Cai W, (2011) Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med 4: 32-42.
23. Mendelson DS, Gordon MS, Rosen LS, Hurwitz H, Wong MK, et al. (2010) Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J Clin Oncol 28: 15s.
24. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, et al. (2011) Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38: 1335-1343.
25. Cai W, Chen K, He L, Cao Q, Koong A, et al. (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34: 850-858.
26. Cai W, Niu G, Chen X, (2008) Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 35: 186-208.
27. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, et al. (2007) Quantitative radioimmunoPET imaging of EphA2 in tumour-bearing mice. Eur J Nucl Med Mol Imaging 34: 2024-2036.
28. Delgado R, Sun Y, Motekaitis RJ, Martell AE, (1993) Stabilities of divalent and trivalent metal ion complexes of macrocyclic triazatriacetic acids. Inorg Chem 32: 3320-3326.
29. Clarke ET, Martell AE, (1991) Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands. Inorg Chim Acta 190: 27-36.
30. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, et al. (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47: 1465-1474.
31. Tannock IF, Rotin D, (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373-4384.
32. Hong H, Benink HA, Zhang Y, Yang Y, Uyeda HT, et al. (2011) HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res 3: 392-403.
33. Yang Y, Zhang Y, Hong H, Liu G, Leigh BR, et al. (2011) In vivo near-infrared fluorescence imaging of CD105 expression. Eur J Nucl Med Mol Imaging 38: 2066-2076.
34. Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, et al. (2011) Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging: Epub.
35. Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, et al. (2011) Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 22: 1729-1735.
36. Wang H, Cai W, Chen K, Li ZB, Kashefi A, et al. (2007) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34: 2001-2010.
37. Takahashi N, Haba A, Matsuno F, Seon BK, (2001) Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61: 7846-7854.
38. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, et al. (2000) Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6: 2037-2043.